Global Companion Animal Cardiac Drugs Market to Hit USD 4.67 Bn by 2035 | CAGR 8.32%

Read more about this report- Global Companion Animal Cardiac Drugs Market to Hit USD 4.67 Bn by 2035 | CAGR 8.32%

 

• The Companion Animal Cardiac Drugs Market has a 2024 value of USD 1.94 billion, which is projected to increase to USD 4.67 billion by the year 2035, with a CAGR of about 8.32% between the years 2025 and 2035. It is indicative of a growing need for sophisticated cardiovascular care in pets due to the rise in awareness of pet health and veterinary care.
• The increasing number of pets having heart diseases like congestive heart failure, hypertension, arrhythmia, and dilated cardiomyopathy is one of the principal causes of increased use of cardiac drugs. Increased focus on early diagnosis and suitable therapies to enhance the quality of life and longevity. To the extent that pet owners view animals as family members, there is more focus on early diagnosis and effective treatments to help them live longer and better.
• Examples of products in this market are ACE inhibitors, beta blockers, diuretics, calcium channel blockers, antiarrhythmic drugs, vasodilators, and other related drugs. These medications are also available in oral and injectable variations to guarantee effective treatment of numerous animal health conditions.
• Disease indication, animal type, route of administration, distribution channel, and end user market segmentation assist companies in targeting particular therapeutic requirements. Small animals such as dogs, cats, and other animals are the top patient groups, and are treated in veterinary hospitals, retail drugstores, online drugstores, and utilized by pet owners, animal research centers, and animal shelters.
• Other advantages of this segmentation include manufacturers being able to innovate in terms of new formulations, better modes of drug delivery, and wider therapeutic indications, thus leading to its adoption and market growth.
• The increased penetration of premium cardiac drugs is being driven by online veterinary pharmacies and digital healthcare sites that provide convenience, home delivery, and informational assistance to pet owners, as a result of which they constitute a greater degree of penetration into this specific market segment.
• High levels of pet ownership, well-developed veterinary facilities, and well-adapted preventative and therapeutic treatment make North America and Europe dominate the market. The Asia-Pacific market is a high-growth market with increasing disposable incomes, urbanization, and more pet adoptions.
• The major players in the market are Zoetis Inc., Boehringer Ingelheim Animal Health, Elanco Animal Health Incorporated, and Ceva Santé Animale. These players are oriented towards the development of their therapeutic portfolios, the development of research in the field of cardiac health, and the extension of their presence across the world in order to build stronger leadership in the market.